SCHEMBL774098

SCHEMBL774098

C=CC(=O)NCc1cccnc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 2/20 0.68
RECQL P46063 1/20 0.64
MAPT P10636 2/20 0.59
ALDH1A1 P00352 1/20 0.58
POLB P06746 1/20 0.58
FES P07332 1/20 0.57
RET P07949 1/20 0.57
MARK3 P27448 1/20 0.57
TYK2 P29597 1/20 0.57
FLT4 P35916 1/20 0.57
SYK P43405 1/20 0.57
CLK2 P49760 1/20 0.57
CLK4 Q9HAZ1 1/20 0.57
NPSR1 Q6W5P4 1/20 0.56
CYP1A2 P05177 1/20 0.56
CYP3A4 P08684 1/20 0.56
CYP2C9 P11712 1/20 0.56
CYP2C19 P33261 1/20 0.56
PKM P14618 1/20 0.56
KMT2A Q03164 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31321074 1.00 USP2 (0.68) USP2RECQLMAPTALDH1A1POLB
SCHEMBL31321078 1.00 USP2 (0.68) USP2RECQLMAPTALDH1A1POLB
SCHEMBL2698425 0.85 USP2 (0.70) USP2RECQLMAPTALDH1A1POLB
SCHEMBL2334562 0.84 POLB (0.55) USP2RECQLPOLBLMNA
SCHEMBL427121 0.81 RECQL (0.70) USP2RECQLMAPTALDH1A1FES
SCHEMBL10157136 0.81 USP2 (0.65) USP2RECQLMAPTALDH1A1POLB
SCHEMBL29460250 0.81 FES (0.81) RECQLMAPTALDH1A1POLBFES
SCHEMBL9130703 0.81 FES (0.81) RECQLMAPTALDH1A1POLBFES
SCHEMBL26129219 0.80 USP2 (0.63) USP2RECQLMAPTALDH1A1POLB
SCHEMBL26125902 0.80 USP2 (0.63) USP2RECQLMAPTALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3554505-A1 METHODS OF TREATING OCULAR DISORDERS Beta Therapeutics Pty. Ltd. (AU) 2019-10-23 EP disclosed
WO-2018107226-A1 METHODS OF TREATING OCULAR DISORDERS Beta Therapeutics Pty. Ltd. (AU) 2018-06-21 WO disclosed
US-8895551-B2 Acrylamide compounds and the use thereof SHIONOGI & CO., LTD. (JP) 2014-11-25 US disclosed
US-20120067236-A1 RESIN COMPOSITION FOR LASER ENGRAVING, RELIEF PRINTING PLATE PRECURSOR FOR LASER ENGRAVING AND PROCESS FOR PRODUCING SAME, AND RELIEF PRINTING PLATE AND PROCESS FOR MAKING SAME FUJIFILM CORPORATION (JP) 2012-03-22 US disclosed
US-20120022069-A1 ACRYLAMIDE COMPOUNDS AND THE USE THEREOF SHIONOGI & CO., LTD. (JP) 2012-01-26 US disclosed
EP-1226138-B1 FAB I INHIBITORS AFFINIUM PHARM INC (CA) 2004-12-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022069-A1 ACRYLAMIDE COMPOUNDS AND THE USE THEREOF TRPA1, TRPV1, CACNA1B USP2 2240/4885RECQL 673/4885MAPT 1518/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.